Skip to Content

Flexion Therapeutics, Inc.

Merger

  • Date:
  • 10/13/2021
  • Company Name:
  • Flexion Therapeutics, Inc.
  • Stock Symbol:
  • FLXN
  • Company Name - Buyer:
  • Pacira BioSciences, Inc.
  • Stock Symbol - Buyer:
  • PCRX
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 10/11/2021

Case Finder

Locate any case using the tools below.

NEW YORK, October 13, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Flexion Therapeutics, Inc. (NASDAQ: FLXN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Pacira BioSciences, Inc. (NASDAQ: PCRX).

On October 11, 2021, Flexion announced that it had entered into an agreement to be acquired by Pacira in an all-cash transaction.  Pursuant to the merger agreement, Flexion stockholders will receive $8.50 in cash, plus one non-tradeable contingent value right (“CVR”) worth up to $8.00 in cash in the event of certain sales and/or regulatory milestones, for each share of Flexion common stock owned.  The deal is scheduled to close in the fourth quarter of 2021.   

Bragar Eagel & Squire is concerned that Flexion’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Flexion’s stockholders.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Flexion Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: